{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.2","upperLimit":"87.1","value":"78.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"The OR was defined as number of participants with a best response of CR or PR. CR requires all of following to be present: No evidence of leukemic cells in peripheral blood and/or by routine H/E staining of bone marrow; Resolution of any hepatomegaly, splenomegaly, and abnormal (\\>=2 cm minimum length) lymphadenopathy by CT or MRI (maximum diameter of spleen should be either \\<17 cm or have decreased by \\>25% from its baseline); normal CBC (Neutrophils \\>=1.5 x 10\\^9/L, Platelets \\>=100 x 10\\^9/L, and hemoglobin \\>=11.0 g/dL) without transfusions or growth factors for at least 4 weeks. PR requires all of following for a period of at least 4 weeks: \\>=50% decrease or normalization (\\<5.0 x 10\\^9/L) in peripheral blood lymphocyte count and \\>=50% reduction in lymphadenopathy and in abnormal haepatosplenomegaly by CT or MRI from pre-treatment baseline value; normal CBC as mentioned above or 50% improvement in CBC values over baseline without transfusions or growth factors for at least 4 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"NUMBER","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Prior to each treatment cycle, end of treatment, and at follow-up visits every 3 months for the next 24 months and every 6 months thereafter (Approximately 6 years)","title":"Percentage of Participants With Objective Response by Investigator's Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}